clinical trial · NCT06285318
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Relapsed/Refractory Multiple Myeloma (RRMM)TeclistamabTalquetamab
brief summary
The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.
started
Dec 18, 2023
primary completion
Jun 30, 2026
completion
Jul 31, 2026
last updated
Apr 13, 2026
official title
A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol